<DOC>
	<DOCNO>NCT00840931</DOCNO>
	<brief_summary>The purpose study find maximum tolerate dose ( MTD ) combine therapy lenalidomide ( Revlimid® ) Granulocyte/macrophage colony stimulate factor CD40 Ligand express K562 cell line ( GM.CD40L ) bystander vaccine . This research also do see well combination drug work fight myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>Immunotherapy Using Lenalidomide + Bystander Vaccine High Risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Fixed dose lenalidomide 10 mg/day , Days 1- 21 28 day treatment cycle , 4 dose escalation GM.CD40L vaccine : 10 X 10^6 GM.CDL cell per vaccination ; 30 X 10^6 GM.CDL cell per vaccination ; 60 X 10^6 GM.CDL cell per vaccination ; 120 X 10^6 GM.CDL cell per vaccination ; Vaccination 2-week interval , day 8 22 , total four 28-day cycle .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must understand voluntarily sign informed consent form Age ≥18 year time signing informed consent form Able comply study visit schedule assessment require protocol Documented diagnosis MDS subtypes Refractory Anemia Excess Blast 1 ( RAEB1 ) ( myeloblast ≥59 % ) Refractory Anemia Excess Blast 2 ( RAEB2 ) ( myeloblast ≥1019 % ) intermediate 2 , Acute myelogenous leukemia bone marrow myeloblast &gt; 30 % high risk define International Prognostic Scoring System ( IPSS ) score refractory anemia excess blast transformation ( RAEBt ) ( myeloblast ≥ 2030 % ) per FrenchAmericanBritish Classification System ( FAB ) criterion . Any single combination cytogenetic abnormality allow . Study treatment offer first line treatment long available food Drug Administration ( FDA ) approve treatment option explain treat physician participant decline option . Study treatment offer patient fail , tolerate wish continue therapeutic agent MDS . Prior chemotherapy allow chemotherapy kind last 4 week prior initiation study therapy . Must able provide adequate bone marrow ( BM ) aspirate biopsy specimen histopathological evaluation , cytogenetic analysis tissue bank screening procedure . Platelet count must &gt; 20,000/ µl without platelet transfusion . Absolute neutrophil count ( ANC ) must &gt; 500/ µl without myeloid growth factor support . Should receive erythropoietin and/or myeloid growth factor least 14 day prior initiation study therapy . Should current diagnosis prior history autoimmune immune deficiency disorder include human immunodeficiency virus positive/acquired immunodeficiency syndrome ( HIV+/AIDS ) . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour start lenalidomide must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . All patient must counsel minimum every 28 day pregnancy precaution risk fetal exposure . Both male female member race ethnic group eligible study . Prior therapy lenalidomide . Proliferative chronic myelomonocytic leukemia ( CMML WBC≥12,000/µL peripheral blood ) , confirm bone marrow biopsy . Acute myelogenous leukemia bone marrow myeloblast ≥30 % MDS secondary treatment radiotherapy , chemotherapy , and/or immunotherapy malignant autoimmune disease exclude . Any follow laboratory abnormality : Serum creatinine &gt; 1.5 x upper limit normal ( ULN ) Serum aspartic transaminase ( AST ) alanine transaminase ( ALT ) &gt; 2.0 x ULN Serum total bilirubin &gt; 2.0 mg/dL ( 34 µmol/L ) Prior ≥ grade2 national Cancer Institute Common Toxicity Criteria ( NCI CTC ) allergic reaction thalidomide . Prior desquamating ( blister ) rash take thalidomide . Prior allergic reaction vaccination sort . Participants ≥ grade2 neuropathy . Clinically significant anemia due factor iron , B12 folate deficiency , autoimmune hereditary hemolysis gastrointestinal bleeding . Use cytotoxic chemotherapeutic agent , growth factor , experimental agent ( agent commercially available ) treatment MDS within 28 day start drug treatment . Prior history malignancy MDS ( except basal cell squamous cell carcinoma carcinoma situ cervix ) unless participant free disease ≥3 year . Any serious medical condition psychiatric illness prevent participant signing informed consent form place participant unacceptable risk he/she participate study . Pregnant nursing female . Use corticosteroid great equivalent prednisone 10mg daily within 4 week first vaccination , ongoing need corticosteroid great equivalent prednisone 10 mg daily</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Myeloid</keyword>
	<keyword>Monocytic</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Vaccine</keyword>
	<keyword>MDS</keyword>
	<keyword>High Risk Myelodysplastic Syndrome</keyword>
</DOC>